Essel D. Al-Saleem, MD

Fox Chase Cancer Center
Philadelphia, PA
USA Papers:
2050 Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model